menu
    • menu
    [{"orgOrder":0,"company":"Restem","sponsor":"Restem","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Umbilical Cord Lining Stem Cell","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Restem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Restem \/ Restem","highestDevelopmentStatusID":"6","companyTruncated":"Restem \/ Restem"},{"orgOrder":0,"company":"Restem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Umbilical Cord Lining Stem Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Restem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Restem \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Restem \/ Undisclosed"},{"orgOrder":0,"company":"Restem","sponsor":"SOLVE FSHD","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Umbilical Cord Lining-Derived Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Restem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Restem \/ SOLVE FSHD","highestDevelopmentStatusID":"6","companyTruncated":"Restem \/ SOLVE FSHD"},{"orgOrder":0,"company":"Restem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Umbilical Cord Outer Lining Stem Cell","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Restem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Restem \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Restem \/ Undisclosed"},{"orgOrder":0,"company":"Restem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Restem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Restem \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Restem \/ Undisclosed"},{"orgOrder":0,"company":"Restem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Restem","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Restem \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Restem \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Restem

    Menu

    Restem

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Restem

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Restem

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Pol...

                            Details : This drug candidate is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Myositis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 08, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Restem

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Restem

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Umbilical Cord Lining-Derived Stem Cell

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : SOLVE FSHD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)

                            Details : Umbilical Cord Lining-Derived Stem Cell is a Cell and Gene therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Muscular Dystrophy, Facioscapulohumeral.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 25, 2025

                            Lead Product(s) : Umbilical Cord Lining-Derived Stem Cell

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : SOLVE FSHD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Restem

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Restem

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Umbilical Cord Outer Lining Stem Cell

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RESTEM Receives FDA Fast Track Designation for Restem-L in Inflammatory Myopathy

                            Details : FDA has granted fast track designation for Restem-L, an umbilical cord outer lining stem cells (ULSCs) program for the treatment of polymyositis and dermatomyositis.

                            Product Name : Restem-L

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 07, 2025

                            Lead Product(s) : Umbilical Cord Outer Lining Stem Cell

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Restem

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Restem

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            RESTEM Gets FDA Orphan Drug Designation for ULSC in Polymyositis and Dermatomyositis

                            Details : Umbilical cord outer lining stem cells (ULSCs) program is being investigated for the treatment of Polymyositis (PM) and Dermatomyositis (DM).

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 03, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Restem

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Restem

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Umbilical Cord Lining Stem Cell

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Recipient : University of Florida

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)

                            Details : Umbilical Cord Lining Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Polymyositis.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 25, 2021

                            Lead Product(s) : Umbilical Cord Lining Stem Cell

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Recipient : University of Florida

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Restem

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Restem

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Umbilical Cord Lining Stem Cell

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS

                            Details : Umbilical Cord Lining Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 31, 2020

                            Lead Product(s) : Umbilical Cord Lining Stem Cell

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth